These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37695138)
21. Functional food addressing heart health: do we have to target the gut microbiota? Ryan PM; Ross RP; Fitzgerald GF; Caplice NM; Stanton C Curr Opin Clin Nutr Metab Care; 2015 Nov; 18(6):566-71. PubMed ID: 26406391 [TBL] [Abstract][Full Text] [Related]
22. Trimethylamine Canyelles M; Tondo M; Cedó L; Farràs M; Escolà-Gil JC; Blanco-Vaca F Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347638 [TBL] [Abstract][Full Text] [Related]
23. The use of an in-vitro batch fermentation (human colon) model for investigating mechanisms of TMA production from choline, L-carnitine and related precursors by the human gut microbiota. Day-Walsh P; Shehata E; Saha S; Savva GM; Nemeckova B; Speranza J; Kellingray L; Narbad A; Kroon PA Eur J Nutr; 2021 Oct; 60(7):3987-3999. PubMed ID: 33934200 [TBL] [Abstract][Full Text] [Related]
24. Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases. He S; Jiang H; Zhuo C; Jiang W Cardiovasc Toxicol; 2021 Aug; 21(8):593-604. PubMed ID: 34003426 [TBL] [Abstract][Full Text] [Related]
25. Interaction between gut microbiome and cardiovascular disease. Peng J; Xiao X; Hu M; Zhang X Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177 [TBL] [Abstract][Full Text] [Related]
26. Role of the Gut Microbiome in the Development of Atherosclerotic Cardiovascular Disease. Al Samarraie A; Pichette M; Rousseau G Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982492 [TBL] [Abstract][Full Text] [Related]
27. Gut microbiota and microbiota-derived metabolites in cardiovascular diseases. Chen X; Zhang H; Ren S; Ding Y; Remex NS; Bhuiyan MS; Qu J; Tang X Chin Med J (Engl); 2023 Oct; 136(19):2269-2284. PubMed ID: 37442759 [TBL] [Abstract][Full Text] [Related]
28. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Ussher JR; Lopaschuk GD; Arduini A Atherosclerosis; 2013 Dec; 231(2):456-61. PubMed ID: 24267266 [TBL] [Abstract][Full Text] [Related]
29. Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis. Li D; Kirsop J; Tang WH Curr Diab Rep; 2015 Sep; 15(9):63. PubMed ID: 26208694 [TBL] [Abstract][Full Text] [Related]
30. Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases. Garg Y; Kanwar N; Chopra S; Tambuwala MM; Dodiya H; Bhatia A; Kanwal A Endocr Metab Immune Disord Drug Targets; 2022; 22(14):1344-1356. PubMed ID: 35761484 [TBL] [Abstract][Full Text] [Related]
31. Trimethylamine N-Oxide Generated by the Gut Microbiota: Potential Atherosclerosis Treatment Strategies. Zhu B; Ren H; Xie F; An Y; Wang Y; Tan Y Curr Pharm Des; 2022; 28(35):2914-2919. PubMed ID: 36121073 [TBL] [Abstract][Full Text] [Related]
32. Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease? He M; Tan CP; Xu YJ; Liu Y Food Res Int; 2020 Dec; 138(Pt B):109812. PubMed ID: 33288187 [TBL] [Abstract][Full Text] [Related]
33. Dietary factors, gut microbiota, and serum trimethylamine-N-oxide associated with cardiovascular disease in the Hispanic Community Health Study/Study of Latinos. Mei Z; Chen GC; Wang Z; Usyk M; Yu B; Baeza YV; Humphrey G; Benitez RS; Li J; Williams-Nguyen JS; Daviglus ML; Hou L; Cai J; Zheng Y; Knight R; Burk RD; Boerwinkle E; Kaplan RC; Qi Q Am J Clin Nutr; 2021 Jun; 113(6):1503-1514. PubMed ID: 33709132 [TBL] [Abstract][Full Text] [Related]
34. Transmission of atherosclerosis susceptibility with gut microbial transplantation. Gregory JC; Buffa JA; Org E; Wang Z; Levison BS; Zhu W; Wagner MA; Bennett BJ; Li L; DiDonato JA; Lusis AJ; Hazen SL J Biol Chem; 2015 Feb; 290(9):5647-60. PubMed ID: 25550161 [TBL] [Abstract][Full Text] [Related]
35. Tangeretin Mitigates Trimethylamine Oxide Induced Arterial Inflammation by Disrupting Choline-Trimethylamine Conversion through Specific Manipulation of Intestinal Microflora. Cao Y; Leng C; Lin K; Li Y; Zhou M; Zhou M; Shu X; Liu W Molecules; 2024 Mar; 29(6):. PubMed ID: 38542959 [TBL] [Abstract][Full Text] [Related]
36. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder. Luqman A; Hassan A; Ullah M; Naseem S; Ullah M; Zhang L; Din AU; Ullah K; Ahmad W; Wang G Front Immunol; 2024; 15():1321395. PubMed ID: 38343539 [TBL] [Abstract][Full Text] [Related]
37. Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD). Hemmati M; Kashanipoor S; Mazaheri P; Alibabaei F; Babaeizad A; Asli S; Mohammadi S; Gorgin AH; Ghods K; Yousefi B; Eslami M Life Sci; 2023 Sep; 329():121947. PubMed ID: 37463653 [TBL] [Abstract][Full Text] [Related]
38. Methodological considerations for the identification of choline and carnitine-degrading bacteria in the gut. Jameson E; Quareshy M; Chen Y Methods; 2018 Oct; 149():42-48. PubMed ID: 29684641 [TBL] [Abstract][Full Text] [Related]